1,E. 1/25/02



02012282

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

25 January 2002

GlaxoSmithKline plc (Name of registrant)

GLAXO WELLCOME HOUSE, BERKELEY AVENUE, GREENFORD, MIDDLESEX UB6 0NN (Address of principal executive offices) PROCESSED

(FEB 2 0 2002

THOMSON
FINANCIAL

Indicated by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ____ Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ____ No ___



GlaxoSmithKline plc Berkeley Avenue Greenford Middlesex UB6 0NN

Tel: +44 (0)20 8966 8000 Fax. +44 (0)20 8966 8330 www.gsk.com DX 124740 Greenford 2

Directors' Interests

I give below details of changes in directors' interests in the Ordinary Shares of GlaxoSmithKline plc.

24 January 2002

The Administrators of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") notified GlaxoSmithKline plc on the 25 January 2002, that as a result of movement in the fund on the 24 January 2002, the number of Ordinary Share ADRs held by the fund had decreased from 18,857,362 to 18,589,142 at an average price of \$49.9200.

The Plan is a discretionary fund of which all employees or former employees of SmithKline Beecham plc and its subsidiaries are potential beneficiaries. One of the Company's directors, Dr J P Garnier is therefore, interested in the shares held in the fund from time to time in the same way as other employees or former employees of SmithKline Beecham plc and its subsidiaries.

S M Bicknell Company Secretary

25 January 2002

GlaxoSmithKline plc Registered in England & Wales No. 3888792 Registered office Glaxo Wellcome House Berkeley Avenue, Greenford Middlesex. UB6 0NN

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: 25 January 2002

By: VICTORIA LLEWELLYN

Victoria Llewellyn

Authorised Signatory for and on behalf of GlaxoSmithKline plc